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CO Ϭϳϱ Ͳ TRUNK FAT INCREASE IS PREVENTED BOTH IN PATIENTS UNDERGOING LONGͲ
LASTING  CONTINUOUS  RͲHGH  THERAPY  AND  IN  THOSE  WHO  DISCONTINUED  RͲHGH
COMPARED TO UNTREATED PATIENTS͗ RESULTS FROM BASELINE DATA OF THE MAGHD
STUDY͘
M͘ L͘ MŽŶǌaŶiϭ͕ E͘ MagŶaŶiϭ͕ C͘ Diaǌǌiϭ͕ S͘ PedeƌǌŽůiϭ͕ L͘ VŽůƉiϭ͕ V͘ RŽchiƌaϭ
ϭUŶiƚà OƉeƌaƚiǀa di EŶdŽcƌiŶŽůŽgia͕ UŶiǀeƌƐiƚà di MŽdeŶa e ReggiŽ Eŵiůia MŽdeŶa
BacŬgƌŽƵŶd͗ Adult  growth  hormone  (GH)  deficiency  (AGHD)  is  related  with  alterations  in  body
composition, increased abdominal and visceral adiposity, adverse change in lipid and carbohydrate
metabolism, and reduction of bone mineral density (BMD).
Aŝŵ͗ To compare baseline outcomes concerning body composition and biochemical/hormonal data
among adult patients with AGHD referring to a single endocrinological center and grouped according to
their history of r-hGH therapy.
MeƚŚŽdƐ͗ The Management of Adult Growth Hormone Deficiency Study ;MAGHD) is a prospective,
single-center trial aiming to improve AGHD management through a smartphone app (MAGHD App:
Manage AGHD) and a wearable device integrated with a software framework able to merge several
kind of patients’ daily data with clinical data collected in institutional databases.
Up-to-now, a total of ϳϰ subjects (Ϯϲ Female, ϰϴ Male, mean age: ϱϲ.ϲнϭϰ.ϴ years) with AGHD, fulfilling
the inclusion criteria, were enrolled in the study. According to r-hGH therapy, they were divided in ϯ
groups: patients on long-term r-hGH therapy (Group ϭ, nсϯϯ), patients previously treated with r-hGH,
who had stopped the therapy at any time (Group Ϯ, nсϭϴ), patients never treated (Group ϯ, nсϮϯ). Each
patient has completed the baseline visit, including biochemical and hormonal measurements and data
on BMD and body composition obtained by DXA. The nonparametric Kruskal-Wallis test was used for
comparison among ϯ groups and data are expressed as median. Only baseline data are here shown.
ReƐƵůƚƐ͗ Mean duration of AGHD disease of the entire cohort was ϭϮϭ.ϮнϭϬϱ.ϴ months; it was lower in
Group ϯ compared to both Group ϭ and Ϯ (pфϬ.Ϭϱ). Waist circumference (Group ϭ ϵϱ cm; Group Ϯ ϵϲ,ϱ
cm; Group ϯ ϭϬϵ cm), total fat mass (Group ϭ ϮϱϬϭϲ g; Group Ϯ Ϯϲϰϵϭ g; Group ϯ ϯϯϴϴϳ g) and trunk fat
mass (Group ϭ ϭϭϳϰϯ g;  Group Ϯ ϭϮϱϵϴ g;  Group ϯ ϭϲϳϲϭ g)  were significantly higher in Group ϯ
compared to both Group Ϯ and ϭ (pфϬ.Ϭϱ),  while total  fat mass and trunk fat mass did not differ
significantly among Group ϭ and Ϯ. Serum insulin and total body fat (й) were significantly higher in
Group ϯ than Group ϭ (pфϬ.Ϭϱ). IGF-ϭ and IGFBPϯ were significantly higher in Group ϭ compared to
both Group Ϯ and ϯ (pфϬ.ϬϬϬϭ). BMD, circulating lipids, and fasting glucose did not differ among the ϯ
groups.
CŽŶcůƵƐŝŽŶƐ͗ r-hGH therapy seems to confer a long-lasting beneficial effect on body fat, especially trunk
fat, even after its discontinuation in AGHD patients, but not on metabolic parameters.
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